Evaluation method and evaluation device for aneurysm and machine readable storage medium

Abstract

The invention discloses an aneurysm evaluation method and device and a machine readable storage medium. The evaluation method comprises the following steps: determining the correlation between hemodynamic parameters and inflammation in a to-be-evaluated region; and based on the determined correlation, evaluating the aneurysm condition of the area to be evaluated. Therefore, the accuracy of the evaluation result of the aneurysm is improved.

Description

Technical Field

[0001] The present application relates to the technical field of aneurysms, and more specifically, to an aneurysm evaluation method and evaluation device and a machine-readable storage medium. Background Art

[0002] Intracranial aneurysm is a cerebrovascular disease that may rupture at any time, and once ruptured, it may endanger the patient's life.

[0003] The current evaluation of aneurysms is mainly based on the big data summary of past cases, and the aneurysms are evaluated by weighting multiple influencing factors such as the patient's basic conditions and aneurysm morphology based on the results of retrospective studies. The evaluation of aneurysms by summarizing multiple risk factors in the past lacks systematic theoretical guidance, and the evaluation results are not accurate.

[0004] Therefore, how to improve the accuracy of aneurysm assessment results becomes a technical problem that needs to be solved in this field. Summary of the invention

[0005] In view of this, the present application proposes an aneurysm assessment method and an assessment device and a machine-readable storage medium to improve the accuracy of the aneurysm assessment results.

[0006] In a first aspect, the present application provides an aneurysm assessment method, the assessment method comprising: determining the correlation between hemodynamic parameters and inflammation in a region to be assessed; and based on the determined correlation, assessing the aneurysm condition of the region to be assessed.

[0007] Optionally, determining the correlation between the hemodynamic parameters and inflammation in the area to be evaluated includes: for the area to be evaluated, determining the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after injection of contrast agent, so as to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated.

[0008] Optionally, for the area to be evaluated, the change in tumor wall enhancement before and after the injection of contrast agent is characterized based on the change in brightness before and after the injection of contrast agent.

[0009] Optionally, the evaluation method further includes: determining whether inflammation in the area to be evaluated is obvious; wherein the evaluation of the aneurysm condition in the area to be evaluated is also based on the determination result of whether inflammation in the area to be evaluated is obvious.

[0010] Optionally, the aneurysm condition of the area to be evaluated is evaluated, including: when the inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, determining the area to be evaluated as an aneurysm growth risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, determining the area to be evaluated as an aneurysm rupture risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, determining the area to be evaluated as an area for further evaluation; and / or when the inflammation in the area to be evaluated is not obvious, determining the area to be evaluated as an area to be observed.

[0011] Optionally, when the changes in tumor wall enhancement before and after the injection of contrast agent are characterized based on the changes in brightness before and after the injection of contrast agent, determining whether the inflammation in the area to be evaluated is obvious includes: determining whether the inflammation in the area to be evaluated is obvious based on the changes in brightness of the area to be evaluated and a preset inflammation obvious standard.

[0012] Optionally, determining the correlation between hemodynamic parameters and inflammation in the area to be evaluated includes: determining the correlation coefficient between the hemodynamic parameters and inflammation for the area to be evaluated, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient; and determining the correlation based on the determined correlation coefficient.

[0013] Optionally, the hemodynamic parameter is wall shear stress.

[0014] In a second aspect, the present application also provides an aneurysm evaluation device, which includes: a first determination module, used to determine the correlation between hemodynamic parameters and inflammation in the area to be evaluated; and an evaluation module, used to evaluate the aneurysm condition of the area to be evaluated based on the determined correlation.

[0015] Optionally, the first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: for the area to be evaluated, determining the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after injection of contrast agent, so as to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated.

[0016] Optionally, for the area to be evaluated, the change in tumor wall enhancement before and after the injection of contrast agent is characterized based on the change in brightness before and after the injection of contrast agent.

[0017] Optionally, the evaluation device further comprises: a second determination module, used to determine whether inflammation in the area to be evaluated is obvious; wherein the evaluation module evaluates the aneurysm condition of the area to be evaluated based on the determination result of whether inflammation in the area to be evaluated is obvious.

[0018] Optionally, the evaluation module evaluates the aneurysm condition of the area to be evaluated, including: when the inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, determining the area to be evaluated is an aneurysm growth risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, determining the area to be evaluated is an aneurysm rupture risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, determining the area to be evaluated is an area for further evaluation; and / or when the inflammation in the area to be evaluated is not obvious, determining the area to be evaluated is an area to be observed.

[0019] Optionally, when the changes in tumor wall enhancement before and after the injection of contrast agent are characterized based on the changes in brightness before and after the injection of contrast agent, the second determination module determines whether the inflammation in the area to be evaluated is obvious, including: determining whether the inflammation in the area to be evaluated is obvious based on the changes in brightness of the area to be evaluated and a preset inflammation obvious standard.

[0020] Optionally, the first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: determining the correlation coefficient between the hemodynamic parameters and inflammation for the area to be evaluated, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient; and determining the correlation based on the determined correlation coefficient.

[0021] Optionally, the hemodynamic parameter is wall shear stress.

[0022] In a third aspect, the present application further provides an aneurysm assessment device, the assessment device comprising: a memory; and a processor coupled to the memory, the processor being configured to execute the above-mentioned assessment method based on instructions stored in the memory.

[0023] In a fourth aspect, the present application further provides a machine-readable storage medium having instructions stored thereon, which, when executed by a processor, configure the processor to execute the steps according to the above-mentioned evaluation method.

[0024] According to the technical solution of the present application, the correlation between hemodynamic parameters and inflammation is determined in the area to be evaluated, and the aneurysm condition of the area to be evaluated is evaluated according to the determined correlation, so that the aneurysm condition is evaluated; in the technical solution of the present application, the aneurysm condition of the area to be evaluated is evaluated based on the correlation between hemodynamic parameters and inflammation in the area to be evaluated, and the hemodynamic parameters and inflammation can reflect the current state of the aneurysm in the area to be evaluated. Therefore, the evaluation of the aneurysm condition of the area to be evaluated based on the correlation between hemodynamic parameters and inflammation is based on the current state of the aneurysm. The evaluation result is more accurate, which improves the accuracy of the aneurysm evaluation result. In addition, the development of aneurysms in the entire lesion area is complex. In the technical solution of the present application, the evaluation of the aneurysm condition of the area to be evaluated based on the correlation between hemodynamic parameters and inflammation in the area to be evaluated can be carried out in real time without limiting the scope of the area to be evaluated. Therefore, the scope of the area to be evaluated can be divided into a smaller area, eliminating mutual interference between different areas, and the evaluation of the development of aneurysms in the entire lesion area is more detailed, further improving the accuracy of the aneurysm evaluation result.

[0025] Other features and advantages of the present application will be described in detail in the subsequent detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The accompanying drawings constituting a part of the present application are used to provide a further understanding of the present application, and the schematic implementation modes and descriptions of the present application are used to explain the present application. In the accompanying drawings:

[0027] Figure 1 A flowchart of a method for evaluating an aneurysm according to a preferred embodiment of the present application; and

[0028] Figure 2 It is a structural block diagram of an aneurysm assessment device according to a preferred embodiment of the present application. DETAILED DESCRIPTION

[0029] The technical solution of the present application will be described in detail below with reference to the accompanying drawings and in combination with the implementation modes.

[0030] In a first aspect, embodiments of the present application provide a method for evaluating an aneurysm.

[0031] Figure 1 FIG. 1 is a flow chart of a method for evaluating an aneurysm according to a preferred embodiment of the present application. Figure 1 As shown, the evaluation method includes the following contents.

[0032] In step S10, the correlation between the hemodynamic parameters and inflammation in the region to be evaluated is determined. In other words, for the region to be evaluated, the correlation between the hemodynamic parameters and inflammation in the region is determined. Specifically, for the region to be evaluated, it is determined whether the hemodynamic parameters are correlated or uncorrelated with the inflammation, or whether the hemodynamic parameters are positively correlated, negatively correlated, or uncorrelated with the inflammation.

[0033] In the embodiments of the present application, the area to be evaluated can be determined according to the specific situation, and there is no limitation on this. For example, the area to be evaluated can be the entire lesion area of ​​an aneurysm in a certain part of the body, or it can be a part of the entire lesion area. In addition, the hemodynamic parameters can be determined according to the specific situation.

[0034] In step S11, based on the determined correlation, the aneurysm condition of the area to be evaluated is evaluated. Specifically, it is determined whether the aneurysm in the area to be evaluated is at risk of growth, at risk of rupture, unclear and requires further evaluation, or only requires further observation, and the area to be evaluated is evaluated as one of the following: an aneurysm growth risk area, an aneurysm rupture risk area, an area to be further evaluated, or an area to be observed.

[0035] In the embodiments of the present application, there are many ways to quantify inflammation. For example, inflammation can be quantified by detecting the inflammatory response. Alternatively, inflammation can be quantified by detecting the reaction of the area to be evaluated with other substances. Alternatively, in the embodiments of the present application, inflammation can be characterized by changes in tumor wall enhancement before and after injection of contrast agent, thereby quantifying inflammation.

[0036] Optionally, in an embodiment of the present application, determining the correlation between hemodynamic parameters and inflammation in the area to be evaluated may include the following: For the area to be evaluated, determining the correlation between hemodynamic parameters and changes in tumor wall enhancement before and after contrast agent injection to determine the correlation between hemodynamic parameters and inflammation in the area to be evaluated.

[0037] In the embodiment of the present application, the contrast agent can be determined according to the specific situation, and there is no limitation on this. For example, the contrast agent can be a gadolinium agent.

[0038] Optionally, in an embodiment of the present application, the brightness change before and after the contrast agent is injected can be used to characterize the tumor wall enhancement change before and after the contrast agent is injected.

[0039] Optionally, in an embodiment of the present application, there are many ways to characterize the brightness change before and after the injection of contrast agent. For example, the brightness difference can be used to characterize the brightness change. Specifically, the brightness difference can be obtained by processing the images before and after the injection of contrast agent. Alternatively, the brightness change can be characterized by the change in magnetic resonance signal intensity. Optionally, the difference in magnetic resonance signal intensity can be used to characterize the change in magnetic resonance signal intensity. Specifically, the difference in magnetic resonance signal intensity is obtained by subtracting the magnetic resonance signal intensity before the injection of contrast agent from the magnetic resonance signal intensity after the injection of contrast agent.

[0040] Optionally, in the embodiment of the present application, the magnetic resonance scanning may be performed based on the black blood technology.

[0041] Optionally, in an embodiment of the present application, for the area to be evaluated, determining the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after the injection of contrast agent may include the following contents.

[0042] Before contrast agent injection, the area to be evaluated is scanned for the first time to obtain the first magnetic resonance signal intensity of each pixel in the area to be evaluated. After contrast agent injection, the area to be evaluated is scanned for the second time to obtain the second magnetic resonance signal intensity of each pixel in the area to be evaluated. For each pixel in each pixel, a difference operation is performed on the first magnetic resonance signal intensity and the second magnetic resonance signal intensity to determine the difference in magnetic resonance signal intensity before and after contrast agent injection. The difference operation may be the second magnetic resonance signal intensity minus the first magnetic resonance signal intensity.

[0043] The hemodynamic parameters of each pixel point in the area to be evaluated are determined. For example, the hemodynamic parameter is the wall shear stress.

[0044] The correlation coefficient is determined based on the difference in magnetic resonance signal intensity corresponding to each pixel point in the area to be evaluated and the hemodynamic parameter.

[0045] Based on the determined correlation coefficient, the correlation between the hemodynamic parameters and the difference between the magnetic resonance signal intensity is determined, thereby determining the correlation between the hemodynamic parameters and the change in the magnetic resonance signal intensity, that is, determining the correlation between the hemodynamic parameters and the brightness change before and after the injection of contrast agent, and further determining the correlation between the hemodynamic parameters and the tumor wall enhancement change before and after the injection of contrast agent.

[0046] Optionally, in an embodiment of the present application, for the area to be evaluated, the difference in the ratio of the magnetic resonance signal intensity can be used to characterize the change in the magnetic resonance signal intensity, wherein, for the area to be evaluated, the ratio of the magnetic resonance signal intensity is the ratio of the magnetic resonance signal intensity to the control magnetic resonance signal intensity, and the control magnetic resonance signal intensity is the magnetic resonance signal intensity of the control area. In this way, the systematic error of the scanning device itself can be eliminated, the accuracy of the determined change in the magnetic resonance signal intensity before and after the injection of the contrast agent can be improved, and the accuracy of the aneurysm assessment results can be further improved. For example, the patient's non-lesion area or an artificial in vitro contrast agent can be used as a control area. The non-lesion area of ​​different patients is different. In an embodiment of the present application, the non-lesion area can be the following areas or parts of the following areas: pituitary area, ventricle area, intracranial artery area, intracranial vein area, brain parenchyma area, brainstem area, cerebrospinal fluid area.

[0047] The following uses the pituitary region as a control region as an example to illustrate how to determine the difference in the ratio of the magnetic resonance signal intensity of each pixel before and after the injection of the contrast agent. Other non-lesion regions or artificial in vitro contrast agents can be understood by referring to the following content when used as control regions.

[0048] When the area to be evaluated is scanned before contrast agent injection, the pituitary region is also scanned. The magnetic resonance signal intensity of each pixel point in the pituitary region is obtained, and the magnetic resonance signal intensity of each pixel point in the pituitary region is mathematically operated to determine the third magnetic resonance signal intensity of the pituitary region before contrast agent injection. The mathematical operation can be summation, averaging, weighted averaging, etc.

[0049] The first magnetic resonance signal intensity of each pixel point in the above-mentioned area to be evaluated is divided by the third magnetic resonance signal intensity to obtain a ratio of the first magnetic resonance signal intensity to the third magnetic resonance signal intensity, which is marked as the first magnetic resonance signal intensity ratio.

[0050] When the area to be evaluated is scanned after contrast agent injection, the pituitary region is also scanned. The magnetic resonance signal intensity of each pixel in the pituitary region is obtained, and the magnetic resonance signal intensity of each pixel is mathematically calculated to determine the fourth magnetic resonance signal intensity of the pituitary region after contrast agent injection. The mathematical calculation can be summing, averaging, weighted averaging, etc.

[0051] The second magnetic resonance signal intensity of each pixel point in the above-mentioned area to be evaluated is divided by the fourth magnetic resonance signal intensity to obtain a ratio of the second magnetic resonance signal intensity to the fourth magnetic resonance signal intensity, which is marked as the second magnetic resonance signal intensity ratio.

[0052] For each pixel point in the area to be evaluated, a difference operation is performed on the first magnetic resonance signal intensity ratio and the second magnetic resonance signal intensity ratio to obtain the difference in the ratio of the magnetic resonance signal intensities before and after the contrast agent is injected. The difference operation may be the second magnetic resonance signal intensity ratio minus the first magnetic resonance signal intensity ratio.

[0053] Optionally, in an embodiment of the present application, the assessment of the aneurysm condition of the area to be assessed is also based on the severity of inflammation in the area to be assessed.

[0054] Specifically, in the embodiment of the present application, the evaluation method also includes the following contents. Determine whether the inflammation in the area to be evaluated is obvious. The evaluation of the aneurysm condition in the area to be evaluated is also based on the determination result of whether the inflammation in the area to be evaluated is obvious. In this way, the evaluation result of the aneurysm can be made more accurate, further improving the accuracy of the evaluation result of the aneurysm.

[0055] In the embodiments of the present application, obvious inflammation indicates that the severity of inflammation reaches the preset obvious inflammation standard, and non-obvious inflammation indicates that the severity of inflammation does not reach the preset obvious inflammation standard. Among them, the preset obvious inflammation standard characterizes the severity of inflammation when the inflammation is obvious, and the preset obvious inflammation standard can be determined according to the specific situation. In addition, when different contents are used to quantify inflammation, the contents of the preset obvious inflammation standard are also different.

[0056] For example, when using the changes in tumor wall enhancement before and after contrast agent injection to characterize inflammation, the preset inflammation significance standard can be set for the changes in tumor wall enhancement before and after contrast agent injection. Specifically, the specific degree of the changes in tumor wall enhancement before and after contrast agent injection when inflammation significance is reached is set.

[0057] Optionally, in an embodiment of the present application, the aneurysm condition of the area to be evaluated is evaluated, including the following contents.

[0058] When inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, the area to be evaluated is determined to be an aneurysm growth risk area, and the aneurysm in the area to be evaluated is at risk of growth. And / or, when inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, the area to be evaluated is determined to be an aneurysm rupture risk area, and the aneurysm in the area to be evaluated is at risk of rupture. And / or, when inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, the area to be evaluated is determined to be an area to be further evaluated, and the aneurysm situation in the area to be evaluated is unclear and requires further evaluation. For example, the area to be evaluated can be further divided and evaluated in smaller areas. And / or, when inflammation in the area to be evaluated is not obvious, the area to be evaluated is determined to be an area to be observed, and the aneurysm situation in the area to be evaluated is stable and only further observation is required.

[0059] The technical solution provided in the embodiments of the present application can predict both aneurysm rupture and growth, and the prediction range is wider.

[0060] Optionally, in an embodiment of the present application, when the changes in tumor wall enhancement before and after contrast agent injection are characterized based on the changes in brightness before and after contrast agent injection, determining whether inflammation in the area to be evaluated is obvious may include the following.

[0061] Based on the brightness change of the area to be evaluated and the preset inflammation obvious standard, determine whether the inflammation in the area to be evaluated is obvious. Specifically, when the brightness change of the area to be evaluated reaches the preset inflammation obvious standard, it is determined that the inflammation in the area to be evaluated is obvious; when the brightness change of the area to be evaluated does not reach the preset inflammation obvious standard, it is determined that the inflammation in the area to be evaluated is not obvious. It should be noted that when determining whether the inflammation is obvious or not, the judgment is made based on the overall brightness change of the area to be evaluated.

[0062] Optionally, in an embodiment of the present application, the change in the intensity of the magnetic resonance signal before and after the injection of the contrast agent can be used to characterize the change in brightness before and after the injection of the contrast agent. Specifically, the difference in the intensity of the magnetic resonance signal is used or the difference in the ratio of the intensity of the magnetic resonance signal is used to characterize the change in the intensity of the magnetic resonance signal. Then, the preset standard of obvious inflammation can be that the difference in the intensity of the magnetic resonance signal of the area to be evaluated is greater than or equal to a preset difference threshold, or that the difference in the ratio of the intensity of the magnetic resonance signal of the area to be evaluated is greater than or equal to a preset ratio difference threshold.

[0063] Optionally, in the implementation manner of the present application, the preset difference threshold may be determined according to specific circumstances. For example, the value range of the preset difference threshold may be greater than or equal to 100 and less than or equal to 1000. Preferably, the preset difference threshold may be 500.

[0064] Optionally, in the implementation manner of the present application, the preset ratio difference threshold value may be determined according to the specific situation. For example, the value range of the preset ratio difference threshold value may be greater than or equal to 0.1 and less than or equal to 1. Optionally, the value range of the preset ratio difference threshold value may be greater than or equal to 0.5 and less than or equal to 1. Preferably, the preset ratio difference threshold value may be 0.5.

[0065] When the difference in magnetic resonance signal intensity is used to characterize the change in magnetic resonance signal intensity, it can be determined whether the inflammation in the area to be evaluated is obvious based on the following content.

[0066] The difference in the magnetic resonance signal intensity of each pixel point in the area to be evaluated before and after the injection of the contrast agent is obtained according to the above content, and a mathematical operation is performed to obtain the difference in the magnetic resonance signal intensity of the area to be evaluated, wherein the mathematical operation may be summing, averaging, weighted averaging, etc. The difference in the magnetic resonance signal intensity of the area to be evaluated is compared with a preset inflammation obvious standard to determine whether the obtained difference is greater than or equal to a preset difference threshold, thereby determining whether the inflammation of the area to be evaluated is obvious.

[0067] When the difference in the ratio of magnetic resonance signal intensities is used to characterize the change in magnetic resonance signal intensity, it can be determined whether the inflammation in the area to be evaluated is obvious according to the following content.

[0068] The difference in the ratio of the magnetic resonance signal intensities before and after the injection of the contrast agent at each pixel point in the area to be evaluated obtained according to the above content is subjected to mathematical operation to obtain the difference in the ratio of the magnetic resonance signal intensities of the area to be evaluated, wherein the mathematical operation may be summing, averaging, weighted averaging, etc. The difference in the ratio of the magnetic resonance signal intensities of the area to be evaluated is compared with the preset inflammation obvious standard to determine whether the obtained ratio difference is greater than or equal to the preset ratio difference threshold, thereby determining whether the inflammation of the area to be evaluated is obvious.

[0069] Optionally, in an embodiment of the present application, determining the correlation between hemodynamic parameters and inflammation in the area to be evaluated may include the following contents.

[0070] For the area to be evaluated, the correlation coefficient between the hemodynamic parameter and inflammation is determined, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient. Based on the determined correlation coefficient, the correlation is determined. Specifically, a preset correlation standard is set, wherein the preset correlation standard indicates the corresponding relationship between the correlation coefficient and correlation and irrelevance, or indicates the corresponding relationship between the correlation coefficient and positive correlation, negative correlation and irrelevance.

[0071] Optionally, in an embodiment of the present application, determining the correlation between the hemodynamic parameters and inflammation in the area to be evaluated may also include the following: Based on the determined correlation coefficient, determining the statistical significance parameter p value. Determining the correlation between the hemodynamic parameters and inflammation in the area to be evaluated is also based on the determined statistical significance parameter p value.

[0072] Optionally, in the embodiment of the present application, determining the correlation based on the determined correlation coefficient and the determined statistical significance parameter p-value may include the following contents.

[0073] When the determined correlation coefficient is greater than or equal to a preset correlation coefficient threshold and the determined statistical significance parameter p-value is less than a preset p-value threshold, the correlation is determined to be a positive correlation.

[0074] And / or, when the determined correlation coefficient is less than a preset correlation coefficient threshold and the determined statistical significance parameter p-value is less than a preset p-value threshold, the correlation is determined to be a negative correlation.

[0075] And / or, when the determined statistical significance parameter p-value is greater than or equal to a preset p-value threshold, the correlation is determined to be irrelevant.

[0076] Optionally, in the implementation manner of the present application, the preset correlation coefficient threshold and / or the preset p-value threshold may be determined according to the specific situation. For example, the preset correlation coefficient threshold may be 0. For another example, the value range of the preset p-value threshold may be greater than or equal to 0.001 and less than or equal to 0.3. Optionally, the preset p-value threshold may be 0.05.

[0077] Optionally, in an embodiment of the present application, the area to be evaluated is divided into a plurality of value points, and the hemodynamic parameters and the changes in tumor wall enhancement before and after the injection of contrast agent are determined for each value point. When the determined correlation coefficient is the Spearman correlation coefficient, it can be calculated based on the following formula: Where r represents the determined correlation coefficient, n represents the total number of value points in the area to be evaluated; d i Indicates the rank difference of the hemodynamic parameters and the tumor wall enhancement change at the value point i. Specifically, the area to be evaluated is scanned, and the difference in magnetic resonance signal intensity or the difference in the ratio of magnetic resonance signal intensity is used to characterize the tumor wall enhancement change before and after the injection of the contrast agent, and the pixel point is the above-mentioned value point.

[0078] Optionally, in an embodiment of the present application, the area to be evaluated is divided into a plurality of value points, and the hemodynamic parameters and the changes in tumor wall enhancement before and after the injection of contrast agent are determined for each value point. When the determined correlation coefficient is the Pearson correlation coefficient, it can be calculated based on the following formula: Where r represents the determined correlation coefficient; x i represents the hemodynamic parameter at the value point i; Represents the average value of the hemodynamic parameters of all value points; i represents the change of tumor wall enhancement at point i; It represents the average value of the tumor wall enhancement change of all value points.

[0079] Optionally, in an embodiment of the present application, the area to be evaluated is divided into multiple value points, and the hemodynamic parameters and the changes in tumor wall enhancement before and after contrast agent injection are determined for each value point. The statistical significance parameter p value can be determined based on the following content.

[0080] The t-statistic is calculated based on the following formula: Wherein, r represents the determined correlation coefficient; n represents the total number of value points in the area to be evaluated.

[0081] The degrees of freedom are calculated based on the following formula: df=n-2, where df represents the degrees of freedom.

[0082] Use the obtained t statistic and degrees of freedom to find the corresponding p value.

[0083] Alternatively, use the cumulative distribution function (CDF) of the t-distribution to calculate the p-value. The p-value is the two-tailed probability of the t-statistic: p = 2·P(T>|t|). Where P(T>|t|) is the one-tailed probability corresponding to the absolute value of the t-statistic under the degrees of freedom df of the t-distribution, which can be determined by looking up a t-distribution table or using statistical software.

[0084] Alternatively, use the cumulative distribution function (CDF) of the t-distribution to calculate the p-value. p = 2·(1-P(T≤|t|). P(T≤|t|) is the probability that the t-statistic is less than or equal to |t| under the cumulative distribution function (CDF) of the t-distribution, which can be determined by looking up a t-distribution table or using statistical software.

[0085] Optionally, in the embodiments of the present application, Python may be used to calculate the correlation coefficient and the P value.

[0086] Optionally, in an embodiment of the present application, the hemodynamic parameter is wall shear stress. During the development of aneurysms, abnormally high wall shear stress will damage the arterial wall, thereby increasing the risk of aneurysm formation and growth; abnormally low wall shear stress will cause blood congestion and inflammation and thickening of the aneurysm wall, leading to the risk of aneurysm rupture. In an embodiment of the present application, the development of aneurysms can be predicted by calculating the correlation between aneurysm wall shear stress (WSS) and aneurysm wall enhancement changes.

[0087] Optionally, in an embodiment of the present application, determining the wall shear stress of each pixel point in the area to be evaluated may include the following contents.

[0088] The blood flow information of each pixel point in the area to be evaluated is determined, wherein the blood flow information includes the magnitude and direction of the flow velocity. For each pixel point, the wall shear stress is determined based on the determined blood flow information.

[0089] Specifically, the wall shear stress is determined based on the following formula: Where, μ represents the dynamic viscosity; y represents the distance from the pixel to the wall of the aneurysm; v parallel Represents the velocity of the pixel point parallel to the wall; y=0 represents the position of the wall.

[0090] Optionally, in the embodiment of the present application, in addition to using the above formula to calculate the wall shear stress, a formula derived from the above formula or an estimated formula can also be used to calculate the wall shear stress. For example, WSS = (4μv) / r (μ is the dynamic viscosity, v is the blood flow velocity, and r is the inner diameter of the blood vessel). Or, WSS = 0.5ρC f U 2 (ρ is the fluid density; C f is the friction coefficient of the tube wall; U is the blood flow velocity parallel to the tube wall)

[0091] In the embodiments of the present application, there are many ways to obtain blood flow information, for example, based on one of the following: 4D-Flow scanning, computational fluid dynamics simulation, and a method for calculating blood flow velocity parameters based on the time and concentration changes of contrast agents arriving and passing through blood vessels through CTA and DSA.

[0092] Optionally, in the embodiment of the present application, a 3D-TOF MRA scan can be performed on the site of the patient's aneurysm (e.g., intracranial) to construct the vascular morphology, determine the specific location of the aneurysm, and then determine the area to be evaluated, and then perform the evaluation. In addition, other methods can also be used to determine the specific location of the aneurysm.

[0093] Through the technical solution provided in the implementation mode of the present application, the occurrence, development and possibility of rupture of aneurysms can be evaluated by measuring the interaction between blood flow and the aneurysm wall, and the aneurysm development can be evaluated based on the systematic theoretical guidance related to the occurrence and development of aneurysms, which can improve the accuracy of the aneurysm assessment results.

[0094] The technical solution provided in the implementation mode of the present application can be based on the theory of the effect of hemodynamics on aneurysms. The development of aneurysms can be evaluated by measuring indicators and examining the interaction between the current aneurysm wall and blood flow indicators. It does not evaluate the risk of aneurysms based on a summary of known risk factors, which can further improve the accuracy of the aneurysm assessment results.

[0095] The technical solution provided in the implementation mode of the present application uses fewer factors to evaluate the aneurysm condition, has fewer variables, and a single influencing factor, which is convenient for quantitative evaluation and control; the evaluation is based on the actual situation of the patient, and the parameter information comes from the patient himself, which is not affected by the summarized experience and the differences between specific individuals. Personalized predictions can be made, which can further improve the accuracy of the aneurysm evaluation results.

[0096] The technical solution provided in the implementation mode of the present application uses the mechanism of action of wall shear stress in hemodynamics on aneurysm wall and the relationship between aneurysm wall enhancement changes and wall shear stress as prediction basis. The feasibility of this theory has been confirmed in clinical experiments.

[0097] In a second aspect, an embodiment of the present application provides an aneurysm assessment device.

[0098] Figure 2 FIG. 1 is a structural block diagram of an aneurysm assessment device according to a preferred embodiment of the present application. Figure 2 As shown, the evaluation device includes a first determination module 1 and an evaluation module 2. The first determination module 1 is used to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated. The evaluation module 2 is used to evaluate the aneurysm condition in the area to be evaluated based on the determined correlation.

[0099] Optionally, in an embodiment of the present application, the first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: for the area to be evaluated, determining the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after the injection of contrast agent, so as to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated.

[0100] Optionally, in an embodiment of the present application, for the area to be evaluated, the change in tumor wall enhancement before and after the injection of contrast agent is characterized based on the change in brightness before and after the injection of contrast agent.

[0101] Optionally, in an embodiment of the present application, the evaluation device further includes: a second determination module for determining whether inflammation in the area to be evaluated is obvious; wherein the evaluation module evaluates the aneurysm condition in the area to be evaluated based on the determination result of whether inflammation in the area to be evaluated is obvious.

[0102] Optionally, in an embodiment of the present application, the evaluation module evaluates the aneurysm condition of the area to be evaluated, including: when the inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, determining the area to be evaluated is an aneurysm growth risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, determining the area to be evaluated is an aneurysm rupture risk area; and / or when the inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, determining the area to be evaluated is an area for further evaluation; and / or when the inflammation in the area to be evaluated is not obvious, determining the area to be evaluated is an area for observation.

[0103] Optionally, in an embodiment of the present application, when the changes in tumor wall enhancement before and after the injection of contrast agent are characterized based on the changes in brightness before and after the injection of contrast agent, the second determination module determines whether the inflammation in the area to be evaluated is obvious, including: determining whether the inflammation in the area to be evaluated is obvious based on the changes in brightness of the area to be evaluated and a preset inflammation obvious standard.

[0104] Optionally, in an embodiment of the present application, the first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: determining the correlation coefficient between the hemodynamic parameters and inflammation for the area to be evaluated, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient; and determining the correlation based on the determined correlation coefficient.

[0105] Optionally, in an embodiment of the present application, the hemodynamic parameter is wall shear stress.

[0106] The specific working principle and benefits of the aneurysm evaluation device provided in the embodiment of the present application are similar to the specific working principle and benefits of the aneurysm evaluation method provided in the embodiment of the present application, and will not be repeated here.

[0107] In a third aspect, an embodiment of the present application further provides an aneurysm assessment device, the assessment device comprising: a memory; and a processor coupled to the memory, the processor being configured to execute the assessment method described in the above embodiment based on instructions stored in the memory.

[0108] In a fourth aspect, an embodiment of the present application further provides a machine-readable storage medium having instructions stored thereon, which, when executed by a processor, configure the processor to execute the steps of the evaluation method described in the above embodiment.

[0109] The preferred embodiments of the present application are described in detail above; however, the present application is not limited to the specific details in the above embodiments. Within the technical concept of the present application, a variety of simple modifications can be made to the technical solution of the present application, and these simple modifications all fall within the protection scope of the present application.

[0110] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, this application will not further describe various possible combinations.

[0111] In addition, the various implementation modes of the present application may be arbitrarily combined, and as long as they do not violate the concept of the present application, they should also be regarded as the contents disclosed in the present application.

Claims

1. A method for evaluating an aneurysm, characterized in that: The assessment method includes: Determine the correlation between hemodynamic parameters and inflammation within the region being evaluated; and Based on the determined correlation, the aneurysm condition of the area to be evaluated is evaluated.

2. The evaluation method according to claim 1, characterized in that: Determining the correlation between hemodynamic parameters and inflammation in the region to be evaluated includes: For the area to be evaluated, the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after contrast agent injection is determined to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated.

3. The evaluation method according to claim 2, characterized in that: For the area to be evaluated, the change in tumor wall enhancement before and after the injection of contrast agent is characterized based on the change in brightness before and after the injection of contrast agent.

4. The evaluation method according to any one of claims 1 to 3, characterized in that: The assessment method also includes: Determining whether inflammation is evident in the area to be assessed; The evaluation of the aneurysm condition of the area to be evaluated is also based on the determination result of whether the inflammation of the area to be evaluated is obvious.

5. The evaluation method according to claim 4, characterized in that: The aneurysm condition of the area to be evaluated is evaluated, including: In the case where inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, determining that the area to be evaluated is an aneurysm growth risk area; and / or When inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, determining that the area to be evaluated is an aneurysm rupture risk area; and / or In the case where inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, determining the area to be evaluated as an area to be further evaluated; and / or When the inflammation in the area to be evaluated is not obvious, the area to be evaluated is determined to be an area to be observed.

6. The evaluation method according to claim 4, characterized in that: In the case where the change in tumor wall enhancement before and after contrast medium injection is characterized based on the change in brightness before and after contrast medium injection, determining whether inflammation in the area to be evaluated is significant includes: Based on the brightness change of the area to be evaluated and the preset inflammation obvious standard, it is determined whether the inflammation of the area to be evaluated is obvious.

7. The evaluation method according to claim 1, characterized in that: Determining the correlation between hemodynamic parameters and inflammation in the region to be evaluated includes: For the area to be evaluated, determining a correlation coefficient between the hemodynamic parameter and inflammation, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient; and Based on the determined correlation coefficient, the correlation is determined.

8. The evaluation method according to claim 1, characterized in that: The hemodynamic parameter is wall shear stress.

9. An aneurysm assessment device, characterized in that: The evaluation device includes: A first determination module is used to determine the correlation between hemodynamic parameters and inflammation in the area to be evaluated; and The evaluation module is used to evaluate the aneurysm condition of the area to be evaluated based on the determined correlation.

10. The evaluation device according to claim 9, characterized in that The first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: For the area to be evaluated, the correlation between the hemodynamic parameters and the changes in tumor wall enhancement before and after contrast agent injection is determined to determine the correlation between the hemodynamic parameters and inflammation in the area to be evaluated.

11. The evaluation device according to claim 10, characterized in that For the area to be evaluated, the change in tumor wall enhancement before and after the injection of contrast agent is characterized based on the change in brightness before and after the injection of contrast agent.

12. The evaluation device according to any one of claims 9 to 11, characterized in that: The evaluation device also includes: A second determination module is used to determine whether inflammation in the area to be evaluated is obvious; The evaluation module evaluates the aneurysm condition of the area to be evaluated based on a determination result of whether inflammation in the area to be evaluated is obvious.

13. The evaluation device according to claim 12, characterized in that The evaluation module evaluates the aneurysm condition of the area to be evaluated, including: In the case where inflammation in the area to be evaluated is obvious and the determined correlation is a positive correlation, determining that the area to be evaluated is an aneurysm growth risk area; and / or In the case where inflammation in the area to be evaluated is obvious and the determined correlation is a negative correlation, determining that the area to be evaluated is an aneurysm rupture risk area; and / or In the case where inflammation in the area to be evaluated is obvious and the determined correlation is irrelevant, determining the area to be evaluated as an area to be further evaluated; and / or When the inflammation in the area to be evaluated is not obvious, the area to be evaluated is determined to be an area to be observed.

14. The evaluation device according to claim 12, characterized in that In the case where the change in tumor wall enhancement before and after contrast agent injection is characterized based on the change in brightness before and after contrast agent injection, the second determination module determines whether inflammation in the area to be evaluated is obvious, including: Based on the brightness change of the area to be evaluated and the preset inflammation obvious standard, it is determined whether the inflammation of the area to be evaluated is obvious.

15. The evaluation device according to claim 9, characterized in that The first determination module determines the correlation between the hemodynamic parameters and inflammation in the area to be evaluated, including: For the area to be evaluated, determining a correlation coefficient between the hemodynamic parameter and inflammation, wherein the determined correlation coefficient is one of the following: Spearman correlation coefficient, Pearson correlation coefficient, Kendall rank correlation coefficient, Hoeffding's D correlation coefficient; and Based on the determined correlation coefficient, the correlation is determined.

16. The evaluation device according to claim 9, characterized in that The hemodynamic parameter is wall shear stress.

17. An aneurysm assessment device, characterized in that: The evaluation device includes: Memory; and A processor coupled to the memory, the processor being configured to execute the evaluation method according to any one of claims 1 to 8 based on instructions stored in the memory.

18. A machine-readable storage medium, characterized in that: The machine-readable storage medium stores instructions, which, when executed by a processor, enable the processor to be configured to perform the steps of the evaluation method according to any one of claims 1 to 8.

Images